

EssilorLuxottica

New Myopia Management Insights and a Strong Scientific Program from EssilorLuxottica at IMC 2024

To take myopia management to the next level, the Group's holistic approach makes the difference, by combining fundamental science to better understand the myopia mechanisms and all the prevention and myopia control solutions, including the promotion and improvement of earlier diagnosis and treatment path.

Charenton-le-Pont, France (October 2, 2024) – EssilorLuxottica significantly contributed to the scientific dialogue at International Myopia Conference (IMC) 2024 held from September 23-28 in Changsha and Sanya, China. The Group presented a comprehensive scientific program, focused on key topics such as holistic myopia management, including myopia prevention, diagnosis, and combination therapy, reinforcing its commitment to advancing myopia research and innovation on a global scale.

Holistic approach to myopia management

As a central aspect of its participation at IMC, EssilorLuxottica showcased its holistic myopia management approach. This strategy expands the focus of myopia care to include not only diagnosis and treatment but also awareness, education, prevention, and long-term follow-up. The objective is to transition from passive management to proactive prevention, ensuring comprehensive and personalized care for children and adolescents.

Key highlights from conference

EssilorLuxottica's strong scientific program featured seven podium presentations by leading experts, alongside eight scientific posters from our R&D team and nine from partners, showcasing latest research and advancements in diagnosis, prevention and management of myopia, including innovative solutions such as Essilor Stellest lenses

Highlights from the pre-IMC event included Dr. Bao Jinhua's (China) compelling five-year results on HAL spectacle lenses, demonstrating their long-term effectiveness in managing myopia. Prof. Mark Bullimore (USA) discussed innovative approaches to evaluating efficacy in myopia control clinical trials, offering fresh perspectives on assessing treatment outcomes, while Dr. Bryan Sim (Singapore) presented the first independent global prospective study combining low-dose atropine with Essilor Stellest lenses in children. Additionally, Dr. Yang Jiwen (China) shed light on combination of optical interventions for managing myopia, underscoring the critical role of combination therapies in future myopia management strategies. The Group also showcased a range of lenses, and instruments at their booth, highlighting a comprehensive, personalized and integrated approach to myopia management.

Focus on myopia prevention

A key focus at IMC was myopia prevention, with significant contributions from Prof. Zhou Xingtao and Prof. Chen Zhi (China). Their recent randomized clinical trial¹ demonstrated that spectacle lenses with highly aspherical lenslets significantly reduced axial length (AL) elongation in pre-myopic children wearing the lenses for over 30 hours per week, establishing a clear dose-response relationship—longer wear time correlated with less AL change. This significant finding supports the new evidence of the use of plano Essilor Stellest lenses for myopia prevention in children who are at risk to develop myopia and paves the way for larger-scale clinical studies.

Innovations and Future Directions in Myopia Management

Norbert Gorny, Chief Scientific Officer, EssilorLuxottica, delivered a compelling talk on the future of myopia management in 2034, where he emphasized the shift to cellular-level discussions regarding myopia mechanisms to enhance our understanding of the condition and its interventions. Wee Sing Ong, R&D EssilorLuxottica (Singapore), presented preliminary findings on the Vision-R™ 800 algorithm for subjective refraction, offering viable alternatives to cycloplegic refraction. Research presented by Sarah Goethals, R&D, EssilorLuxottica (France) revealed that specific retinal ganglion cells can detect defocus by analysing local spatial contrast. This finding enhances our understanding of how the retina modulates eye growth and could enhance the development of myopia control progression lenses by linking optical properties to effective management strategies. Prof. Ranjay Chakraborty (Australia) shared insights into how cyan light impacts myopia development.

In addition, Olga Prenat, Head, Medical & Professional Affairs, EssilorLuxottica, participated in a Global Myopia Public Health Summit, with the participation of the International Agency for Prevention of Blindness. The conference also marked the 60th anniversary of IMC, and EssilorLuxottica contributed to the celebrations with a sponsored video featuring leading minds in myopia research, reflecting on the past, current progress and future directions in myopia management.

"We are convinced that the most recent advancements in our EssilorLuxottica research will play a pivotal role and enable the development of more efficacious solutions while customizing therapies further. This will be instrumental, either for the sake of preventing, delaying the onset of myopia, or significantly improving the efficacy of new lens designs: A crucial asset as personalization will gain more attention in the near future", said Norbert Gorny.

"We were pleased to share the latest findings on myopia and engage with the scientific community at IMC," said Olga Prenat *"These important research results not only enhance clinical studies but also establish a strong foundation for developing long-term, safe, and effective myopia solutions. "Looking to the future, myopia prevention and personalized end-to-end management, including combination therapy, are key. This approach empowers eye care professionals to make informed decisions and promotes earlier diagnosis and intervention. We are looking forward to the 20th Edition of IMC which will be held in Houston in 2026".*

Footnote

Essilor Stellest lenses are currently not available in all countries.

1.Zhe Zhang, Li Zeng, Dantong Gu, Bingjie Wang, Pauline Kang, Kathleen Watt, Jiaqi Zhou, Xueyi Zhou, Zhuoyi Chen, Danjuan Yang, Can Chen, Xiaoying Wang, Xingtao Zhou, Zhi Chen, Spectacle Lenses With Highly Aspherical Lenslets for Slowing Axial Elongation and Refractive Change in Low-Hyperopic Chinese Children: A Randomized Controlled Trial, American Journal of Ophthalmology, Volume 269, 2025, Pages 60-68, ISSN 0002-9394, <https://doi.org/10.1016/j.ajo.2024.08.020>.

Contacts

Olga Prenat
Head of Medical &
Professional Affairs
E pre nato@essilor.fr

Marco Catalani
Head of Corporate Communications
E media@essilorluxottica.com

About EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. With over 200,000 employees across 150 countries, 650 operations facilities and 18,000 stores, its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. EssilorLuxottica is home to the most advanced lens technologies including Varilux, Essilor Stellest and Transitions, the most iconic eyewear brands including Ray-Ban and Oakley, the most desired luxury licensed brands and world-class retailers including LensCrafters and Sunglass Hut. The Company's OneSight EssilorLuxottica Foundation has given access to sustainable vision care to more than 760 million people in underserved communities. The EssilorLuxottica share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESLX.PA; Bloomberg: EL:FP, www.essilorluxottica.com